Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 6,113

Document Document Title
WO/2005/063699A1
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected ...  
WO/2005/063222A1
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.  
WO/2005/063018A1
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...  
WO/2005/061445A1
Methods and reagents for rhodium-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon­ isotope labeled compounds are useful as radiopharmaceuticals, especially for use in ...  
WO/2005/061443A2
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R1 to R15 have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate products ...  
WO2005020899A3
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/058798A2
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.  
WO2005033230A3
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-­containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...  
WO/2005/056519A1
The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optional...  
WO/2005/056520A1
This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatmen...  
WO2002068380A8
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.  
WO2005037798A3
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...  
WO2005009943A3
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...  
WO2004052845A8
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...  
WO2005028445A3
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R <1> is halogen, hydroxy, C 1-6 álkyl,...  
WO/2005/047249A1
The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula (I) wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaceutical compositi...  
WO2005015158A9
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...  
WO/2005/044787A1
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...  
WO/2005/044810A1
&agr -, β-, and &gammad -amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Fo...  
WO/2005/044007A1
A pesticide having stabilized high pesticidal effects for crop plants infected with plant diseases, is presented. The pesticide contains a biphenyl derivative represented by the formula (I) or its salt, as an active ingredient: wherein X...  
WO/2005/044786A1
This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention ha...  
WO/2005/044788A1
A process for producing a compound (C) represented by the formula (C) (wherein R1 means hydrogen, C1-6 alkyl, or C3-8 cycloalkyl; and R2 means hydrogen or methoxy), characterized by reacting a compound (A-1) represented by the formula (A...  
WO/2005/041684A2
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...  
WO2005000803A8
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO/2005/040101A1
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These c...  
WO/2005/040100A1
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...  
WO/2005/040355A2
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...  
WO/2005/037798A2
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...  
WO2005007091A3
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...  
WO2004062601A3
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...  
WO/2005/035471A1
An ether derivative represented by the formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof: (I) (wherein the symbols are the same as defined in the description) and an ether derivative represented by the formul...  
WO/2005/033230A2
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-­containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...  
WO2004103281A3
One aspect of the invention relates to antagonists of mammalian vanilloid receptors. Another aspect of the invention relates to a method of modulating the activity of a vanilloid receptor in a mammal, comprising administering a compound ...  
WO/2005/028445A2
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, h...  
WO2005007732A3
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...  
WO2004064730A3
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.  
WO2004046162A8
ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclo...  
WO/2005/020899A2
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/021499A1
The present application describes modulators of MCP-1 of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/019174A1
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...  
WO2005000803A3
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...  
WO/2005/015158A2
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...  
WO/2005/012231A1
An aminocarbonyl naphthol derivative represented by the formula (1) below and a method for producing the same. (1) (In the formula (1), Y1 and Y2 represent a group selected from the group consisting of aminocarbonyl groups, carboxyl grou...  
WO2004077511A3
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...  
WO/2005/009940A1
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.  
WO/2005/009944A1
The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.  
WO/2005/009943A2
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...  
WO/2005/007732A2
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...  
WO/2005/007621A2
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...  
WO/2005/007091A2
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...  

Matches 551 - 600 out of 6,113